ZYMEWORKS INC. Earnings Per Share (Diluted)
ZYMEWORKS INC. (ZYME) reported Earnings Per Share (Diluted) of -$0.62 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- ZYMEWORKS INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.62, a 2166.67% decline year-over-year.
- ZYMEWORKS INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.59.
- ZYMEWORKS INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.54.
- ZYMEWORKS INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.26.
- ZYMEWORKS INC. earnings per share, diluted for fiscal 2025 was -$1.08.
- ZYMEWORKS INC. earnings per share, diluted for fiscal 2024 was -$1.62.
- ZYMEWORKS INC. earnings per share, diluted for fiscal 2023 was -$1.72, a 190.53% decline from fiscal 2022.
- ZYMEWORKS INC. earnings per share, diluted for fiscal 2022 was $1.90.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.62 10-Q · filed 2026-08-06 | -$1.21 10-Q · filed 2026-08-06 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.59 10-Q · filed 2026-05-07 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.40 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.08 10-K · filed 2026-03-02 |
| 2025-09-30 | -$0.26 10-Q · filed 2025-11-06 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.53 10-Q · filed 2025-11-06 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.03 10-Q · filed 2026-08-06 | -$0.27 10-Q · filed 2026-08-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.30 10-Q · filed 2026-05-07 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.50 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.62 10-K · filed 2026-03-02 |
| 2024-09-30 | -$0.39 10-Q · filed 2025-11-06 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.30 10-Q · filed 2025-11-06 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2024-06-30 | -$0.49 10-Q · filed 2025-08-07 | -$0.91 10-Q · filed 2025-08-07 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.53 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2024-03-31 | -$0.42 10-Q · filed 2025-05-08 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2023-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$1.72 10-K · filed 2026-03-02 |
| 2023-09-30 | -$0.41 10-Q · filed 2024-10-31 | -$1.16 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$1.53 10-Q · filed 2024-10-31 | $3.02 derived: net income ÷ weighted average shares · filed 2025-03-05 |
| 2023-06-30 | -$0.76 10-Q · filed 2024-08-01 | -$1.13 10-Q · filed 2024-08-01 | $3.49 derived: net income ÷ weighted average shares · filed 2025-03-05 | $2.78 derived: net income ÷ weighted average shares · filed 2025-03-05 |
| 2023-03-31 | -$0.37 10-Q · filed 2024-05-02 | $4.27 derived: net income ÷ weighted average shares · filed 2025-03-05 | $3.55 derived: net income ÷ weighted average shares · filed 2025-03-05 | $2.59 derived: net income ÷ weighted average shares · filed 2025-03-05 |
| 2022-12-31 | $4.64 derived: net income ÷ weighted average shares · filed 2025-03-05 | $3.93 derived: net income ÷ weighted average shares · filed 2025-03-05 | $2.96 derived: net income ÷ weighted average shares · filed 2025-03-05 | $1.90 10-K · filed 2025-03-05 |
| 2022-09-30 | -$0.72 10-Q · filed 2023-11-07 | -$1.69 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.86 10-Q · filed 2023-11-07 | -$3.81 derived: net income ÷ weighted average shares · filed 2024-03-06 |
| 2022-06-30 | -$0.97 10-Q · filed 2023-08-10 | -$2.15 10-Q · filed 2023-08-10 | -$3.12 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$4.34 derived: net income ÷ weighted average shares · filed 2024-03-06 |
| 2022-03-31 | -$1.19 10-Q · filed 2023-05-08 | -$2.16 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$3.39 derived: net income ÷ weighted average shares · filed 2024-03-06 | |
| 2021-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$2.19 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$4.61 10-K · filed 2024-03-06 | |
| 2021-09-30 | -$1.25 10-Q · filed 2022-11-08 | -$3.66 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | -$3.58 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |